Around one in five people live with a disability. Yet in Australia and abroad, long waitlists, high costs, and fragmented systems often prevent families from accessing the therapy they need. In some regions, delays extend beyond a year, with little support available in the meantime.
Clinicians, too, face growing challenges – 41% of paediatric specialists report burnout, and the demand for allied health services is increasing at a rate that outpaces workforce growth.
Theratrak provides a practical solution. Founded by paediatric occupational therapist Laura Simmons, the company combines clinical expertise with digital innovation to address growing pressures in the allied health sector.
By digitising therapy programs, connecting care teams, and enabling real-time reporting, Theratrak helps families embed therapy into everyday life and allows therapists to track progress efficiently. It aims to support allied health professionals streamline home therapy programs, increase engagement, and reduce admin burden. This leaves clinicians to focus on what they do best – providing the best participant care.
The result is stronger engagement between appointments, continuity of care despite waitlists, and measurable improvement in outcomes.
Importantly, the platform delivers dual impact of making therapy more accessible for children while creating more sustainable ways of working for allied health professionals.
Market potential
The opportunity is significant. The total addressable market for behavioural health alone is forecast to reach US$40 billion by 2033. With a SaaS subscription model, the ability to scale across multiple disciplines, and a defensible data platform under construction, Theratrak is positioned for both commercial growth and sector-wide impact.
Therapists describe the platform as “a game-changer,” while caregivers say it helps them stay consistent with therapy at home. Independent research has shown statistically significant reductions in psychological distress for participants who used Theratrak while waiting for traditional services.
Early progress
Theratrak has already achieved significant traction with more than 380 paying subscribers and 3,500 active patients using the platform today, with its global adoption extending beyond Australia to the US, UK, Ireland, China and New Zealand..
To date three Electronic Health Record integrations have been completed, integrating Theratrak into clinical systems.
Its enterprise clients include large therapy providers such as Everyday Independence (500+ therapists), the Southern NSW Local Health District, and private practice including RL Therapy Group in California, plus rural and remote healthcare groups.
The company has secured over A$600,000 in grants and funding, including support through Boosting Female Founders, while founder Laura Simmons has also been recognised as a Sidney Myer Innovation Fellow.
The product journey
Theratrak’s strategy is built around phased growth:
- Phase 1 (Live): A therapist-to-family tool for creating and tracking home therapy programs. Already revenue-generating and in daily use.
- Phase 2 (In Development): Expanded features including reporting, compliance, and gamification, now in implementation.
- Phase 3 (Investment-Backed Growth): AI-powered decision support tools and predictive analytics, creating therapy programs tailored to individual needs at scale.
The platform’s proprietary closed data system will provide one of the world’s first real-time insights into therapy outcomes, workforce utilisation, and funding effectiveness – informing better care decisions and more efficient allocation of resources.
The next two years
The immediate focus is to scale Theratrak’s presence in Australia, where adoption of digital solutions in allied health is accelerating. At the same time, the company is building momentum in the US, with early clients already onboard and further research partnerships planned.
Development priorities include:
- Enhancing the automated NDIS reporting tool.
- Completing integrations and gamification features.
- Continuing clinical research in Australia, the US, and overseas.
- Advancing Artificial Intelligence (AI) and Machine Learning (ML) tools for decision support and predictive treatment.
Backing the next stage
Theratrak is now seeking investment to accelerate this expansion, build its team, advance AI-powered tools, and scale in Australia and the US. Additional capital would allow for:
- Team expansion: Hiring a full-time team weighted 60% toward sales and 40% toward technology.
- Product development: Finalising integration projects, expanding gamification features, and continuing AI/ML decision-support tool research and build.
- Market expansion: Implementing sales strategies at scale in Australia and the US, with a view to expanding into global markets.
- Clinical validation: Funding additional research in Australia, the US and other international locations to reinforce the evidence base for the platform.
Interested investors are invited to connect with Laura Simmons to explore how they can be part of reshaping the future of therapy.
Contact Laura at laura@theratrak.co or connect on LinkedIn.
For more on Therartak see www.theratrak.co
Join the OnImpact mailing list to receive the latest impact investment news and updates.